Dataset Information

S100A4 is a high glucose-induced fibrotic factor in Dupuytren’s contracture

ABSTRACT: Dupuytren’s contracture is a superficial fibrotic disease of the hand, which causes flexion contracture of the affected finger. Among several risk factors for Dupuytren’s contracture, diabetes mellitus (DM) is a well-known risk factor for this disease. While epidemiological studies demonstrated a high prevalence of DM in patients with Dupuyren’s contractures, the exact underlying mechanism by which DM is involved in their development and progression are still unknown. Here, we investigate how glycometabolic disorder is involved in the pathogenesis of Dupuytren’s contracture. RNA sequencing reveal that Dupuytren’s contracture-derived fibroblasts treated with high-glucose media upregulated S100A4 (also called fibroblast-specific protein, Fsp1) expression compared to those with low-glucose media. The expression of S100A4 in Dupuytren’s contracture tissues is significantly increased in diabetic patients than in nondiabetic patients. S100A4 is expressed by several types of cells, including fibroblast, myofibroblast and macrophages, however expression of its receptor, Toll-like receptor 4 (TLF4), is observed predominantly in CD68-expressing macrophages. Furthermore, S100A4 treatment significantly increases TGF-β1 expression in macrophages, and pharmacological inhibition of TLR4 decreases TGF-β1. Thus, the S100A4–TLR4–TGF-β axis could be a potential therapeutic target for Dupuytren’s contracture occurring in the diabetic hand.

ORGANISM(S): Homo sapiens

PROVIDER: GSE304250 | GEO | 2026/05/21

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:The inflammatory response after spinal cord injury (SCI) is an important contributor to secondary damage. Infiltrating macrophages can acquire a spectrum of activation states, however, the microenvironment at the SCI site favors macrophage polarization into a pro-inflammatory phenotype, which is one of the reasons why macrophage transplantation has failed. In this study, we investigated the therapeutic potential of the macrophage secretome for SCI recovery. We investigated the effect of the secretome in vitro using peripheral and CNS-derived neurons and human neural stem cells. Moreover, we perform a pre-clinical trial using a SCI compression mice model and analyzed the recovery of motor, sensory and autonomic functions. Instead of transplanting the cells, we injected the paracrine factors and extracellular vesicles that they secrete, avoiding the loss of the phenotype of the transplanted cells due to local environmental cues. We demonstrated that different macrophage phenotypes have a distinct effect on neuronal growth and survival, namely, the alternative activation with IL-10 and TGF-β1 (M(IL-10+TGF-β1)) promotes significant axonal regeneration. We also observed that systemic injection of soluble factors and extracellular vesicles derived from M(IL-10+TGF-β1) macrophages promotes significant functional recovery after compressive SCI and leads to higher survival of spinal cord neurons. Additionally, the M(IL-10+TGF-β1) secretome supported the recovery of bladder function and decreased microglial activation, astrogliosis and fibrotic scar in the spinal cord. Proteomic analysis of the M(IL-10+TGF-β1)-derived secretome identified clusters of proteins involved in axon extension, dendritic spine maintenance, cell polarity establishment, and regulation of astrocytic activation. Overall, our results demonstrated that macrophages-derived soluble factors and extracellular vesicles might be a promising therapy for SCI with possible clinical applications.

Dataset Information

S100A4 is a high glucose-induced fibrotic factor in Dupuytren’s contracture

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets